Processing

Please wait...

Settings

Settings

Goto Application

1. WO2013148690 - TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND DIMETHYL FUMARATE

Publication Number WO/2013/148690
Publication Date 03.10.2013
International Application No. PCT/US2013/033885
International Filing Date 26.03.2013
IPC
A61K 31/4704 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
47042-Quinolinones, e.g. carbostyril
CPC
A61K 31/225
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
21Esters, e.g. nitroglycerine, selenocyanates
215of carboxylic acids
22of acyclic acids, e.g. pravastatin
225Polycarboxylic acids
A61K 31/47
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
A61K 31/4704
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
47Quinolines; Isoquinolines
47042-Quinolinones, e.g. carbostyril
A61K 45/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
A61P 25/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
25Drugs for disorders of the nervous system
28for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Applicants
  • TEVA PHARMACEUTICAL INDUSTRIES LTD. [IL]/[IL] (AE, AG, AL, AM, AO, AT, AU, AZ, BA, BE, BF, BG, BH, BJ, BN, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CL, CM, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GT, GW, HN, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MC, MD, ME, MG, MK, ML, MN, MR, MT, MW, MX, MY, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SY, SZ, TD, TG, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, ZA, ZM, ZW)
  • TEVA PHARMACEUTICALS USA, INC. [US]/[US] (BB)
  • KAYE, Joel, Flaxman [IL]/[IL] (US)
Inventors
  • KAYE, Joel, Flaxman
Agents
  • WHITE, John, P.
Priority Data
13/800,04713.03.2013US
61/616,33727.03.2012US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND DIMETHYL FUMARATE
(FR) TRAITEMENT DE LA SCLÉROSE EN PLAQUES AVEC UNE COMBINAISON DE LAQUINIMOD ET DE FUMARATE DE DIMÉTHYLE
Abstract
(EN)
This invention provides a method of treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome comprising administering to the subject laquinimod as an add-on therapy to or in combination with DMF. This invention also provides a package comprising laquinimod and DMF for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides laquinimod for use as an add-on therapy or in combination with DMF in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention also provides a pharmaceutical composition comprising laquinimod and DMF for use in treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome. This invention further provides use of laquinimod and DMF in the preparation of a combination for treating a subject afflicted with multiple sclerosis or presenting a clinically isolated syndrome.
(FR)
L'invention concerne un procédé de traitement d'un sujet atteint de sclérose en plaques ou présentant un syndrome cliniquement isolé, lequel procédé comprend l'administration au sujet de laquinimod comme thérapie d'appoint au fumarate de diméthyle (DMF) ou en combinaison avec celui-ci. La présente invention concerne également un ensemble comprenant du laquinimod et du DMF pour traiter un sujet atteint de sclérose en plaques ou présentant un syndrome cliniquement isolé. La présente invention concerne également du laquinimod destiné à être utilisé comme thérapie d'appoint au DMF ou en combinaison avec celui-ci pour traiter un sujet atteint de sclérose en plaques ou présentant un syndrome cliniquement isolé. La présente invention concerne également une composition pharmaceutique comprenant du laquinimod et du DMF destinée à être utilisée dans le traitement d'un sujet atteint de sclérose en plaques ou présentant un syndrome cliniquement isolé. La présente invention concerne en outre l'utilisation de laquinimod et de DMF dans la préparation d'une combinaison pour traiter un sujet atteint de sclérose en plaques ou présentant un syndrome cliniquement isolé.
Latest bibliographic data on file with the International Bureau